The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trialAdriaan A. Voors, Piotr Ponikowski, J COMINCOLET et al.|Nature Medicine|2022Cited by 889
Impact of empagliflozin on decongestion in acute heart failure: the EMPULSE trialJan Biegus, Piotr Ponikowski, Adriaan A. Voors et al.|European Heart Journal|2022Cited by 213
Effect of Torsemide vs Furosemide After Discharge on All-Cause Mortality in Patients Hospitalized With Heart FailureRobert J. Mentz, Justice Arhinful, Kevin J. Anstrom et al.|JAMA|2023Cited by 180
Effects of Empagliflozin on Symptoms, Physical Limitations, and Quality of Life in Patients Hospitalized for Acute Heart Failure: Results From the EMPULSE TrialMikhail Kosiborod, Adriaan A. Voors, Christiane E. Angermann et al.|Circulation|2022Cited by 142
Framework to Classify Reverse Cardiac Remodeling With Mechanical Circulatory Support: The Utah-Inova StagesPalak Shah, Stavros G. Drakos, Mitchell A. Psotka et al.|Circulation Heart Failure|2021Cited by 50